BioInvest In The News

Five Prime: A Prime Play on Proteins (9-22-14)
U~T San Diego Isis Pharmaceuticals (9-3-14)
Dick Davis Investment Digest (7-23-14)
The Life Sciences Report (6-19-14)
Moneyshow - Three Favorites from a Biotech Expert (3-12-14)
Dick Davis Investment Digest (1-22-14)
Company Updates
Pharmacyclics Update (9-10-14)

Pharmacyclics Update (9-10-14)

Special Update – PCYC Scores VA Contract, PCYC Shares Still Undervalued – In breaking news, PCYC has been awarded a large Veterans Affairs (VA) contract for Imbruvica.   Details – VA – A Large Buying Group: The following information was posted today (dated September 4, 2014)   Solicitation Number: VA797P14R0033 Contract Award Date: September 4, [...]

Pharmacyclics Update (7-23-14)

Pharmacyclics Update (7-23-14)

SPECIAL UPDATE – PCYC – GILD Severely Restrictive Zydelig Label Underscores Imbruvica’s Superior Profile – Reiterate BUY – Gilead received approval midday for Zydelig (idelalisib) for three blood cancers – refractory CLL, indolent FL and SLL – some what ahead of the August/September PDUFA dates.  While the approvals were widely expected, the strict BLACK BOX [...]

Novavax Update (6-5-14)

Novavax Update (6-5-14)

Novavax (NVAX) – Follow-On Offering Creates Buying Opportunity; Proceeds Will Accelerate “Respiratory Vaccine” Timeline Last night, Novavax announced a $100 million secondary offering of common stock. The underwriters are JPMorgan and Citibank, two global investment banks that currently do not cover the stock from a research standpoint. After speaking with management, the use of proceeds is [...]